Aspect to engineer therapeutic tissues with $20M series A

After spending its early years validating its 3-D bioprinting technology via disease modeling in drug discovery partnerships, Aspect Biosystems raised a $20 million series A round to develop the engineered tissues as therapeutics.

New investor Radical Ventures led the University of British Columbia spinout’s financing. Existing investors Pangaea Ventures and Pallasite Ventures, new investor Rhino Ventures and undisclosed others also participated...